Trending
- Leadless pacemaker is a game-changer for nurse
- AXREM selects its Future Leaders Council members
- CDC expands medical imaging services in Barnsley Town Centre
- Greater Manchester reaches milestone in go-live to support faster diagnoses through PACS-based reporting
- Hermia brand-independent molecular imaging software enables departments to choose the camera they want
- Esaote takes renewed MRI, ultrasound and IT ranges to ECR
- BriTec shares expertise on molecular imaging projects large and small
- Radiation protection solutions will be showcased by Synapse
- Advances in PETCT are helping achieve better treatment options
- Southampton is first UK hospital to add MyLab X90 ultrasound system
The contribution of hybrid imaging to radionuclide therapy
Author(s): Carla Aberu, Paul Gape, Jan Taprogge, Glen Fluxx
Hospital: The Royal Marsden Hospital, The Institute of Cancer Research
Reference: RAD Magazine, 47, 556, 19
Excerpt: Radionuclide therapy is a rapidly evolving field considered a safe and effective targeted approach to treating many types of cancer. Radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate at the site of treatment by physiological mechanisms. Almost all radionuclides used in radionuclide therapy emit photons that can be imaged, enabling non-invasive visualisation of the biodistribution of the therapeutic agent. The combination of functional imaging in nuclear medicine (SPECT, PET) with anatomical imaging in CT, in what is referred to as hybrid imaging, provides undoubted diagnostic value. After many decades of little growth, a dramatic increase in radiotherapeutics heralds what is promising to be a step change in this area of cancer management.